NEWS
Institutional Subscription: Comprehensive Analyses to Enhance Your Global and Local Impact
New Feature: Compare Your Institution with the Previous Year
Find a Professional: Explore Experts Across 197 Disciplines in 221 Countries!
Find a Professional
Print Your Certificate
New! Young University / Institution Rankings 2025
New! Art & Humanities Rankings 2025
New! Social Sciences and Humanities Rankings 2025
Highly Cited Researchers 2025
AD
Scientific Index 2025
Scientist Rankings
University Rankings
Subject Rankings
Country Rankings
Login
Register & Pricing
insights
H-Index Rankings
insights
i10 Productivity Rankings
format_list_numbered
Citation Rankings
subject
University Subject Rankings
school
Young Universities
format_list_numbered
Top 100 Scientists
format_quote
Top 100 Institutions
format_quote
Compare & Choose
local_fire_department
Country Reports
person
Find a Professional
Hm Prince
Peter Maccallum Cancer Centre - Melbourne / Australia
Others
AD Scientific Index ID: 4396644
-
Registration, Add Profile,
Premium Membership
Print Your Certificate
Ranking &
Analysis
Job
Experiences (0)
Education
Information (0)
Published Books (0)
Book Chapters (0)
Articles (0)
Presentations (0)
Lessons (0)
Projects (0)
Subject Leaders
Editorship, Referee &
Scientific Board (0 )
Patents /
Designs (0)
Academic Grants
& Awards (0)
Artistic
Activities (0)
Certificate / Course
/ Trainings (0)
Association &
Society Memberships (0)
Contact, Office
& Social Media
person_outline
Hm Prince's MOST POPULAR ARTICLES
1-)
Lenalidomide plus dexamethasone for relapsed or refractory multiple myelomaM Dimopoulos, A Spencer, M Attal, HM Prince, JL Harousseau, ...New England Journal of Medicine 357 (21), 2123-2132, 200717222007
2-)
Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphomaRL Piekarz, R Frye, M Turner, JJ Wright, SL Allen, MH Kirschbaum, J Zain, ...Journal of clinical oncology 27 (32), 5410, 20097922009
3-)
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myelomaH Quach, D Ritchie, AK Stewart, P Neeson, S Harrison, MJ Smyth, ...Leukemia 24 (1), 22-32, 20106622010
4-)
Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapyB Coiffier, B Pro, HM Prince, F Foss, L Sokol, M Greenwood, D Caballero, ...Journal of Clinical Oncology 30 (6), 631-636, 20127762012
5-)
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a …M Attal, PG Richardson, SV Rajkumar, J San-Miguel, M Beksac, I Spicka, ...The Lancet 394 (10214), 2096-2107, 2019750*2019
ARTICLES
Add your articles
We use cookies to personalize our website and offer you a better experience. If you accept cookies, we can offer you special services.
Cookie Policy
Accept